Upstream / Downstream

Explore pathways related to this product.

Antibody Guarantee

CST Antibody Performance Guarantee

LEARN MORE  

Questions?

Find answers on our FAQs page.

ANSWERS  

Visit PhosphoSitePlus®

PTM information and tools available.

LEARN MORE

Product Includes Quantity Applications Reactivity MW(kDa) Isotype
Phospho-ALK (Tyr1586) (3B4) Rabbit mAb 3348 40 µl
H 80 (NPM-ALK) 220 (ALK) Rabbit IgG
Phospho-Jak3 (Tyr980/981) (D44E3) Rabbit mAb 5031 40 µl
H M 115 Rabbit IgG
Phospho-Jak2 (Tyr1007) (D15E2) Rabbit mAb 4406 40 µl
H M 125 Rabbit IgG
Phospho-Stat3 (Tyr705) (D3A7) XP® Rabbit mAb 9145 40 µl
H M R Mk 79, 86 Rabbit IgG
Phospho-Stat5 (Tyr694) (D47E7) XP® Rabbit mAb 4322 40 µl
H M 90 Rabbit IgG
Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (D13.14.4E) XP® Rabbit mAb 4370 40 µl
H M R Hm Mk Mi Dm Z B Dg Pg Sc 44, 42 Rabbit IgG
Phospho-Akt (Ser473) (D9E) XP® Rabbit mAb 4060 40 µl
H M R Hm Mk Dm Z B 60 Rabbit IgG
Phospho-Src Family (Tyr416) (D49G4) Rabbit mAb 6943 40 µl
H M R Mk 60 Rabbit IgG
Phospho-PLCγ1 (Tyr783) Antibody 2821 40 µl
H M R 155 Rabbit 
Anti-rabbit IgG, HRP-linked Antibody 7074 100 µl
All Goat 

Product Description

The ALK Activation Antibody Sampler Kit provides an economical means to evaluate the activation status of multiple members of the ALK pathway, including phosphorylated ALK, Jak2, Jak3, Stat3, Stat5, PLCγ1, Akt, Src, and p44/42 MAPK. The kit includes enough antibody to perform four western blot experiments with each primary antibody.


Specificity / Sensitivity

Each antibody in the ALK Activation Antibody Sampler Kit recognizes the phosphorylated form of its specific target. Phospho-ALK (Tyr1586) (3B4) Rabbit mAb may cross-react with other activated protein tyrosine kinases including EGFR. Phospho-Jak2 (Tyr1007) (D15E2) Rabbit mAb may cross react with phosphorylated Jak3 and Tyk2. Phospho-Src Family (Tyr416) (D49G4) Rabbit mAb may cross react with overexpressed phosphorylated RTKs.


Source / Purification

Activation state polyclonal antibodies are produced by immunizing animals with a synthetic phosphopeptide corresponding to residues surrounding Tyr783 of human PLCγ1. Polyclonal antibodies are purified by protein A and peptide affinity chromatography. Rabbit monoclonal antibodies are produced by immunizing animals with synthetic phosphopeptides corresponding to residues surrounding Tyr1586 of human ALK, Tyr1007 of human Jak2, Tyr980/981 of human and mouse Jak3, Tyr705 of mouse Stat3, Tyr694 of human Stat5a, Thr202/Tyr204 of human p44 MAP kinase, Ser473 of human Akt, or Tyr416 of human Src.

Anaplastic lymphoma kinase (ALK) is a tyrosine kinase receptor for pleiotrophin (PTN), a growth factor involved in embryonic brain development (1-3). In ALK-expressing cells, PTN induces phosphorylation of both ALK and the downstream effectors IRS-1, Shc, PLCγ, and PI3 kinase (1). ALK was originally discovered as a nucleophosmin (NPM)-ALK fusion protein produced by a translocation (4). Investigators have found that the NPM-ALK fusion protein is a constitutively active, oncogenic tyrosine kinase associated with anaplastic lymphoma (4). Research literature suggests that activation of PLCγ by NPM-ALK may be a crucial step for its mitogenic activity and involved in the pathogenesis of anaplastic lymphomas (5).

A distinct ALK oncogenic fusion protein involving ALK and echinoderm microtubule-associated protein like 4 (EML4) has been described in the research literature from a non-small cell lung cancer (NSCLC) cell line, with corresponding fusion transcripts present in some cases of lung adenocarcinoma. The short, amino-terminal region of the microtubule-associated protein EML4 is fused to the kinase domain of ALK (6-8).


1.  Stoica, G.E. et al. (2001) J Biol Chem 276, 16772-9.

2.  Iwahara, T. et al. (1997) Oncogene 14, 439-49.

3.  Morris, S.W. et al. (1997) Oncogene 14, 2175-88.

4.  Morris, S.W. et al. (1994) Science 263, 1281-4.

5.  Bai, R.Y. et al. (1998) Mol Cell Biol 18, 6951-61.

6.  Takeuchi, K. et al. (2008) Clin Cancer Res 14, 6618-24.

7.  Soda, M. et al. (2007) Nature 448, 561-6.

8.  Rikova, K. et al. (2007) Cell 131, 1190-203.


Entrez-Gene Id 207, 208, 10000, 238, 5595, 5594, 2534, 3055, 3717, 3718, 3932, 4067, 5335, 6714, 6774, 6776, 6777, 7525
Swiss-Prot Acc. P31749, P31751, Q9Y243, Q9UM73, P27361, P28482, P06241, P08631, O60674, P52333, P06239, P07948, P19174, P12931, P40763, P42229, P51692, P07947

Protein Specific References

Germack R and Dickenson JM (2000) Br J Pharmacol 130, 867–74

Wick MJ et al. (2000) J Biol Chem 275, 40400–6

Rane MJ et al. (2001) J Biol Chem 276, 3517–23

Guizzetti M and Costa LG (2001) Neuroreport 12, 1639–42

Brognard J et al. (2001) Cancer Res 61, 3986–97

Maira SM et al. (2001) Science 294, 374–80

Schönherr E et al. (2001) J Biol Chem 276, 40687–92

Hill MM et al. (2001) J Biol Chem 276, 25643–6

Dhawan P et al. (2002) Cancer Res 62, 7335–42

Conus NM et al. (2002) J Biol Chem 277, 38021–8

Sano H et al. (2002) J Biol Chem 277, 19439–47

Egawa K et al. (2002) J Biol Chem 277, 38863–9

Kisseleva MV et al. (2002) J Biol Chem 277, 6266–72

Barry FA and Gibbins JM (2002) J Biol Chem 277, 12874–8

Ikonomov OC et al. (2002) Endocrinology 143, 4742–54

Rani MR et al. (2002) J Biol Chem 277, 38456–61

Ho R et al. (2002) Cancer Res 62, 6462–6

Wan X and Helman LJ (2003) Oncogene 22, 8205–11

Fukuda T et al. (2003) J Biol Chem 278, 51324–33

Kim HH et al. (2003) FASEB J 17, 2163–5

Min YH et al. (2004) Cancer Res 64, 5225–31

Tazzari PL et al. (2004) Br J Haematol 126, 675–81

Matsuzaki H et al. (2004) Biochemistry 43, 4284–93

Wolfrum S et al. (2004) Arterioscler Thromb Vasc Biol 24, 1842–7

Kaneko Y et al. (2004) J Cell Sci 117, 407–15

Esfandiarei M et al. (2004) J Virol 78, 4289–98

Baudhuin LM et al. (2004) FASEB J 18, 341–3

Dietze EC et al. (2004) Oncogene 23, 3851–62

Wu T et al. (2004) Mol Cancer Ther 3, 299–307

Honjo S et al. (2005) DNA Cell Biol 24, 141–7

Karlsson HK et al. (2005) Diabetes 54, 1459–67

Viniegra JG et al. (2005) J Biol Chem 280, 4029–36

Le XF et al. (2005) J Biol Chem 280, 2092–104

Smith E and Frenkel B (2005) J Biol Chem 280, 2388–94

Edwards LA et al. (2005) Oncogene 24, 3596–605

Karlsson HK et al. (2005) Diabetes 54, 1692–7

Kippenberger S et al. (2005) J Biol Chem 280, 3060–7

Jung HS et al. (2005) Mol Endocrinol 19, 2748–59

Khundmiri SJ et al. (2006) Am J Physiol Cell Physiol 291, C1247–57

Hers I and (2007) Blood 110, 4243–52

Ananthanarayanan B et al. (2007) J Biol Chem 282, 36634–41

Zunder ER et al. (2008) Cancer Cell 14, 180–92

Grenegård M et al. (2008) J Biol Chem 283, 18493–504

Abubaker J et al. (2009) Mol Cancer 8, 51

Chen PL and Easton AS (2011) Curr Neurovasc Res 8, 14–24

Van Aller GS et al. (2011) Biochem Biophys Res Commun 406, 194–9

Uesugi A et al. (2011) Cancer Res 71, 5765–78

Ou YH et al. (2011) Mol Cell 41, 458–70

Wang S et al. (2012) PLoS One 7, e37427

Glidden EJ et al. (2012) J Biol Chem 287, 581–8

Shih MC et al. (2012) Oncogene 31, 2389–400

Misra UK and Pizzo SV (2012) J Cell Biochem 113, 1488–500

Johnson AL et al. (2001) Biol Reprod 64, 1566–74

Zhang M and Riedel H (2009) J Cell Biochem 107, 65–75

Syme CA et al. (2005) J Biol Chem 280, 11281–8

Li Z et al. (2001) J Biol Chem 276, 42226–32

Nguyen TH et al. (2002) J Biol Chem 277, 24274–9

Funakoshi-Tago M et al. (2006) EMBO J 25, 4763–72

Ungureanu D et al. (2011) Nat Struct Mol Biol 18, 971–6

Yan D et al. (2012) Blood 120, 1888–98

Alonso A et al. (2004) J Biol Chem 279, 4922–8

Chichili GR and Rodgers W (2007) J Biol Chem 282, 36682–91

Wagner MJ and Smiley JR (2009) J Virol 83, 12452–61

Motiwala T et al. (2010) J Cell Biochem 110, 846–56

Jin LL et al. (2010) J Proteome Res 9, 2752–61

Wang YH et al. (2001) Am J Physiol Cell Physiol 281, C1667–75

Schmitt JM and Stork PJ (2002) Mol Cell 9, 85–94

Abrahamsen H et al. (2003) J Biol Chem 278, 17170–7

Kim M et al. (2004) Oncogene 23, 1645–55

Zhou S et al. (2004) J Biol Chem 279, 54463–9

Ren Y et al. (2004) J Biol Chem 279, 8497–505

Kim HP et al. (2004) Biochem J 379, 141–50

Feistritzer C et al. (2005) Exp Cell Res 305, 214–20

Daoud G et al. (2006) J Physiol 571, 537–53

Eichhorn PJ et al. (2007) PLoS Genet 3, e218

Zhu S et al. (2007) Cancer Res 67, 10129–37

Zhou, J. et al. (2003) J Biol Chem 278, 6936-41.

Ng J and Cantrell D (1997) J Biol Chem 272, 24542–9

Schuringa JJ et al. (2000) Blood 95, 3765–70

Duarte RF and Frank DA (2000) Blood 96, 3422–30

Schuringa JJ et al. (2001) Oncogene 20, 5350–8

Deb A et al. (2001) EMBO J 20, 2487–96

Abe K et al. (2001) Oncogene 20, 3464–74

Kopantzev Y et al. (2002) Oncogene 21, 6791–800

Sun S and Steinberg BM (2002) J Gen Virol 83, 1651–8

Hwang JH et al. (2003) Mol Endocrinol 17, 1155–66

Lo RK et al. (2003) J Biol Chem 278, 52154–65

Liu H et al. (2003) Blood 102, 344–52

Lo RK and Wong YH (2004) Mol Pharmacol 65, 1427–39

Wang R et al. (2005) J Biol Chem 280, 11528–34

Yuan ZL et al. (2005) Science 307, 269–73

Ray S et al. (2005) Gastroenterology 129, 1616–32

Liu AM et al. (2006) J Biol Chem 281, 35812–25

Zhang X et al. (2007) Proc Natl Acad Sci U S A 104, 4060–4

Ohbayashi N et al. (2007) Biol Pharm Bull 30, 1860–4

Nadiminty N et al. (2007) Biochem Biophys Res Commun 359, 379–84

Duechting A et al. (2008) J Virol 82, 7942–52

Chen CL et al. (2008) Mol Cancer 7, 78

Hatziapostolou M et al. (2011) Cell 147, 1233–47

Sestito R et al. (2011) FASEB J 25, 916–27

Gupta M et al. (2012) Leukemia 26, 1356–64

Fox EM et al. (2008) Mol Endocrinol 22, 1781–96


For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.
Select antibodies in this kit are sold under a license from Chemicon International, Inc. relating to U.S. Patent No. 5,658,791.
U.S. Patent No. 5,675,063.